| ²é¿´: 366 | »Ø¸´: 0 | |||
sz280115710½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
·ÒëÒ»ÏÂÂÛÎÄ
|
| Morphy and Rankovic [32] have suggested a unified term¡°designed multiple ligands ¡± (DMLs) i.e., compounds that are rationally designed to exhibit two or more specific pharmacological actions. The advantages of DMLs over the drug combinationsinclude (i) both palliative and disease modifying actions, (ii) addi-tive or synergistic therapeutic responses, (iii) improved drugable characteristics (e.g., blood brain barrier permeability) of the ther-apeutic component, (iv) more predictable PK and PD relationships and (v) prolonged duration of effectiveness [38] . DMLs can be designed as a single molecule either acting on multiple targets or having been capable of exhibiting two or more pharmacological activities in a multifactorial disease. The former types of DMLs can be more appropriately termed as Multitarget compounds (MTCs) while the latter type as Multifunctional compounds (MFCs). |
» ²ÂÄãϲ»¶
µ÷¼ÁÇóÊÕÁô
ÒѾÓÐ7È˻ظ´
272·Ö²ÄÁÏ×ÓÇóµ÷¼Á
ÒѾÓÐ36È˻ظ´
275Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ19È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ33È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ47È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
ÐèÒª°ÑдºÃµÄÖÐÎÄÂÛÎÄ·Òë³ÉÍâÎÄ£¬Ôõô°ì
ÒѾÓÐ5È˻ظ´
Ͷ¡¶ÊýѧÎïÀíѧ±¨¡·µÄÓ¢Îİ棬¾¹ýÂþ³¤µÄµÈ´ýºó£¬ÒªÇó·ÒëÖÐÎÄ·¢±íµÄ£¿½»Á÷һϸÐÏë
ÒѾÓÐ44È˻ظ´
×î½üÏë°ÑÒÔǰµÄ˶ʿÂÛÎÄÖØÐÂÕûÀíһϽá¹û·¢ÏÖÓÐÈË×î½ü°ÑÎÒµÄÂÛÎÄ·¢±íÁË
ÒѾÓÐ9È˻ظ´
ÇëÎÊÖÐÎÄ»áÒéÄÜ·Òë³ÉÓ¢ÎÄ·¢µ½¹úÍâÆÚ¿¯È¥Âð
ÒѾÓÐ3È˻ظ´
Çó´óÉñ°ïÎÒ·ÒëÒ»ÏÂÕâ¶Î»°°¡ ¡¢Ð¡µÜ¸Ð¼¤²»¾¡£¡£¡£¡¼±ÓÃ
ÒѾÓÐ12È˻ظ´
СŮ×Ó½«ÂÛÎÄ·Òë³ÉÓ¢Îĵ¼Ê¦ÈÃͶ»áÒ飬±íʾһµã¾ÑéľÓУ¬ÇóÖú
ÒѾÓÐ7È˻ظ´
Çë°ïæ¿´¿´»Ø¸´Òâ¼ûÔõô·Ò루һ¾ä»°£©
ÒѾÓÐ8È˻ظ´
дÍêÖÐÎÄ·Ò룬»¹ÊÇÖ±½ÓдӢÎÄ
ÒѾÓÐ30È˻ظ´
Çë½Ìһϲ©Ê¿ÂÛÎĵÄд×÷˳Ðò£¿
ÒѾÓÐ9È˻ظ´
×îÐµĹØÓÚ΢ÉúÎï·½ÏòµÄδ±»·Òë¹ýµÄÓ¢ÓïÂÛÎÄ
ÒѾÓÐ3È˻ظ´
ÇëÎÊ´ó¼ÒÓкÃÓÃÒ»µãµÄ·ÒëÈí¼þ»òÕßÍøÕ¾ÍÆ¼öÂð£¿
ÒѾÓÐ3È˻ظ´
¼±Çó´ó¼Ò°ïæ·ÒëÒ»ÏÂÒ»¾äÉó¸å»Ø¸´
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿ÈõÈõµÄÎÊһϹØÓÚÓ¢ÎÄÎÄÏ×·Òë
ÒѾÓÐ21È˻ظ´
Çë¸ßÈ˽øÀ´Ö¸µãһϣº·ÂÕÕһƪӢÎİÑ×Ô¼ºµÄÖÐÎÄÎÄÕ·Òë³ÉÁËÓ¢ÎÄ£¬Ëã²»Ëã³Ï®£¿£¿
ÒѾÓÐ16È˻ظ´
´ó¼Ò°ïæ·Òëһϣ¬Ê²Ã´Òâ˼
ÒѾÓÐ8È˻ظ´
ÓаÑÓ¢ÎÄÂÛÎÄ·Òëһϻ¹ÄÜËãһƪÎÄÕÂÕâÑùµÄÊÂÇéÂð[ÒÔ·ÒëÕßÃûÒå·Ç×÷Õß]£¿
ÒѾÓÐ15È˻ظ´
´ó¼ÒдһƪӢÎÄpaper»¨¶à³¤Ê±¼ä°¡£¬½øÀ´½»Á÷Ò»ÏÂ
ÒѾÓÐ33È˻ظ´
¡¾ÆäËû¡¿´ó¼ÒÀ´ÍƼöһϺÃÓõķÒëÈí¼þ°É
ÒѾÓÐ19È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË













»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´